Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Trial Sites
Back to Top
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase IV | Treatment | Active | Any age | Pharmaceutical / Industry | PRT10T NCT01264822 |
Summary
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori
Eligibility Criteria
Inclusion criteria:
- gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphoma with Helicobacter pylori positive
- The stages of MALT lymphoma are Lugano International Conference classification Stage I or II 1 and Wotherspoon grade 4 or 5
Exclusion criteria:
- With diffuse large B-cell lymphoma
- Have been treated to gastric mucosa-associated lymphoid tissue (MALT) lymphoma
- Corresponding to contraindication of each drug
Trial Lead Organizations/Sponsors
Eisai Incorporated
| Katsuya Sugizaki |  | Study Director |
| Customer & Product Quality Infomation Center | | |
| Email: _ML_CLNCL@hhc.eisai.co.jp | ||
Trial Sites
|
|
|
|
| Japan | |||
|
|||
| Amagasaki-shi | |||
|
|||
| Study Site | |||
| Chuo | |||
|
|||
| Study Site | |||
| Fukuoka | |||
|
|||
| Study Site | |||
| Hamamatsu | |||
|
|||
| Study Site | |||
| Hirakata | |||
|
|||
| Study Site | |||
| Hirosaki | |||
|
|||
| Study Site | |||
| Hiroshima | |||
|
|||
| Study Site | |||
| Hitachi | |||
|
|||
| Study Site | |||
| Isehara | |||
|
|||
| Study Site | |||
| Itabashi | |||
|
|||
| Study Site | |||
| Kashiwa | |||
|
|||
| Study Site | |||
| Kobe | |||
|
|||
| Study Site | |||
| Kurashiki | |||
|
|||
| Study Site | |||
| Kyoto | |||
|
|||
| Study Site | |||
| Matsue | |||
|
|||
| Study Site | |||
| Matsuyama | |||
|
|||
| Study Site | |||
| Minato-ku | |||
|
|||
| Study Site | |||
| Nagano-shi | |||
|
|||
| Study Site | |||
| Nagasaki | |||
|
|||
| Study Site | |||
| Nagoya | |||
|
|||
| Study Site | |||
| Nara | |||
|
|||
| Study Site | |||
| Niigata | |||
|
|||
| Study Site | |||
| Oita-shi | |||
|
|||
| Study Site | |||
| Okayama | |||
|
|||
| Study Site | |||
| Osaka | |||
|
|||
| Study Site | |||
| Osakasayama | |||
|
|||
| Study Site | |||
| Otawara-shi | |||
|
|||
| Study Site | |||
| Saga | |||
|
|||
| Study Site | |||
| Sapporo | |||
|
|||
| Study Site | |||
| Sendai | |||
|
|||
| Study Site | |||
| Shinagawa-ku | |||
|
|||
| Study Site | |||
| Suzaka | |||
|
|||
| Study Site | |||
| Takamatsu | |||
|
|||
| Study Site | |||
| Takatsuki | |||
|
|||
| Study Site | |||
| Tottori | |||
|
|||
| Study Site | |||
| Toyama | |||
|
|||
| Study Site | |||
| Tsuyama | |||
|
|||
| Study Site | |||
| Ube | |||
|
|||
| Study Site | |||
| Yamagata-shi | |||
|
|||
| Study Site | |||
| Yamaguchi | |||
|
|||
| Study Site | |||
| Yufu | |||
|
|||
| Study Site | |||
| Hiroshima | |||
|
|||
| Fukuyama | |||
|
|||
| Study Site | |||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01264822
Information obtained from ClinicalTrials.gov on October 14, 2012
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
